PropertyValue
?:abstract
  • T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.
is ?:annotates of
?:creator
?:doi
  • 10.1038/s41392-019-0070-9
?:doi
?:externalLink
?:journal
  • Signal_Transduct_Target_Ther
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/663eda55622d5106c79727187327cf8b0a1e653e.json
?:pmc_json_files
  • document_parses/pmc_json/PMC6799837.xml.json
?:pmcid
?:pmid
?:pmid
  • 31637014
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • PMC
?:title
  • Genetically engineered T cells for cancer immunotherapy
?:type
?:year
  • 2019-09-20

Metadata

Anon_0  
expand all